Completed Research Studies & Results

If you are thinking about taking part in a research study, including a clinical trial, there’s a lot to consider. Check out our FAQs, as well as our lists of Ongoing Research Studies and results from Past Research Studies below. Please contact us at if you know of any additional studies or results, or if the recruitment status for a study has changed, etc… You may also be interested in our SomnusNooze articles about Research Studies.

Note: If you are interested in trying a clinical trial treatment that is not available in your country, a company like WEP Clinical may be able to help you access this treatment.

DISCLAIMER: This listing is provided merely for informational purposes. Listing a study on this site/web page does not mean that it has been independently evaluated by the Hypersomnia Foundation. The safety and scientific validity of a study listed here is the responsibility of the study sponsor and investigators, not the Hypersomnia Foundation. Before making any decision as to whether or not to participate in a particular research study, you should (1) know the risks and potential benefits of that research study, and (2) consult your own healthcare provider.


Takeda’s Sparkle Studies: Evaluating Novel Orexin 2 Receptor Agonists for IH and Narcolepsy

The SPARKLE studies are testing investigational orexin 2 receptor agonists (intravenous TAK-925 and oral TAK-994) to see if they could potentially be a safe and effective way to help increase wakefulness for people with idiopathic hypersomnia or narcolepsy.

SPARKLE 1501: STOPPED EARLY as of October 2021 (see Takeda's Press Release). This phase 2 study was evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising oral doses of TAK-994 in people with narcolepsy. (See also clinicaltrials.gov info HERE and HERE.)

SPARKLE 2002: RECRUITING/ENROLLMENT COMPLETED as of November 2020 (further info from ClinicalTrials.gov). This phase 1 study was designed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of an intravenous (IV) dose of TAK-925 in adults who have been diagnosed with idiopathic hypersomnia (IH). 

These are follow-ups to Takeda's earlier studies: 1) "Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Patients with Narcolepsy" (further info from ClinicalTrials.gov); 2) "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Patients with Narcolepsy" (further info from ClinicalTrials.gov).

See also Takeda's September 2019 Press Release: New Data Presented at World Sleep Congress Demonstrate Early Signs of Efficacy for TAK-925, a Selective Orexin Type-2 Receptor (OX2R) Agonist, in Patients with Narcolepsy Type 1


Real World Idiopathic Hypersomnia Outcomes Patient Survey

RECRUITMENT COMPLETE as of April 2021 for patients with idiopathic hypersomnia in the U.S. for the Real World Idiopathic Hypersomnia Outcomes Patient Survey.

Jazz Pharmaceuticals, in collaboration with Stratevi and inVibe Labs, is conducting a real-world idiopathic hypersomnia outcomes patient survey to understand patient experiences with idiopathic hypersomnia, how it impacts their lives, and their perspectives regarding their current treatment regimen. Participation involves completing an online survey. The participant may also be selected to answer several open-ended questions through an automated voice response system, which participants would call into using their mobile phone.


Pediatric Hypersomnia Screening Survey

RECRUITMENT COMPLETE as of January 2021. Dr. Kiran Maski, pediatric neurologist and sleep medicine specialist at Boston Children’s Hospital, and a member of the Hypersomnia Foundation’s Medical Advisory Board, has developed a questionnaire that aims to improve screening for narcolepsy and idiopathic hypersomnia, with the goal of helping health care professionals identify hypersomnia symptoms quickly. Boston Children’s Hospital recruited participants between the ages of 8-18 years who had been recently diagnosed (within 1 year) with narcolepsy or idiopathic hypersomnia (or who were awaiting diagnosis with sleep study testing) to answer an online questionnaire. If you would like to learn more about the study, please send an email to Neuro Sleep Research () or call 617-919-6212. More info HERE.


Qualitative Health Research Study on Living With IH

RECRUITMENT COMPLETE as of January 2021. CLICK HERE to review the study flyer.


A Study of the Efficacy and Safety of JZP-258 in the Treatment of IH

RECRUITING COMPLETED as of June 2020. Jazz Pharmaceuticals’ trial of JZP-258 (a low-sodium alternative for Xyrem): CLICK HERE.

Similar study of the Efficacy and Safety of JZP-258 in Subjects with Narcolepsy with CataplexyCLICK HERE (recruitment complete). In July 2020, Jazz Pharmaceuticals announced the U.S. FDA's approval of Xywav (JZP-258), as a treatment for cataplexy or excessive daytime sleepiness in narcolepsy patients.

In August, 2021, the U.S. FDA approved Xywav for IH. Read more HERE.


Newcastle, NSW, Australia Study of Alternative Therapies in Hypersomnia

RECRUITMENT COMPLETE during 2020. The Adult Sleep Laboratory in Newcastle, NSW, Australia recruited adults with IH for a research study investigating the effectiveness of alternative therapies on sleep and daytime alertness. Visit the Sleep Health Foundation website for more information.


Transcranial Direct Current (tDCS) Stimulation Therapy for Central Hypersomnia Without Cataplexy

STUDY TERMINATED due to lack of funding as of July 2020: CLICK HERE. See also: A Pilot Study of tDCS Looks Promising for the Treatment of Idiopathic Hypersomnia.


Validation of Non-Invasive Miniature Optical Sensors for Scoring Sleep Stages

RECRUITMENT COMPLETE as of June 2020: CLICK HERE.


Balance Therapeutics’ Study of Oral BTD-001 in Adults With IH (Arise2)

RECRUITING COMPLETED as of April 2020—adults age 18 to 70 with IH (including those currently on a stimulant regimen) across the USA (and Canada): ClinicalTrials.gov. BTD-001 is a GABA-antagonist that may possibly work similarly to flumazenil.

In 2020, Balance Therapeutics concluded this study, and the data were inconclusive. The company does not plan any further trials related to IH, and they have wound down operations.

Preliminary Results: reported at the 2019 World Sleep Congress.

Results and information from the previous trial, Arise1:

In 2015, Balance Therapeutics announced the launch of the first double-blindplacebo-controlled, crossover, multicenter study of a drug (BTD-001) for the treatment of idiopathic hypersomnia (IH) and type 2 narcolepsy (T2N) in adults (Arise1): CLICK HERE for more information. Results as of December 2017: An open-label study of the efficacy, safety and tolerability of oral BTD-001 in adults with idiopathic hypersomnia or narcolepsy type 2.


Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1

STUDY COMPLETED April 2020: CLICK HERE. DM1 is often associated with hypersomnia. The study purpose is to evaluate the safety and tolerability of ERX-963 and its potential use as a treatment to reduce excessive daytime sleepiness / hypersomnia and improve cognitive function in DM1 participants compared to placebo treatment.

Read more: Viewing Hypersomnias Through the Lens of Myotonic Dystrophy.


Importance of Sleep Deprivation in Differential Diagnosis of Primary Hypersomnia

STUDY COMPLETE as of January 2020: CLICK HERE.


The Role of the Circadian System in Neurological Sleep-Wake Disorders

As of 2020, recruitment status now unknown: CLICK HERE.


Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)

RECRUITING COMPLETE: CLICK HERE. Axsome Therapeutics is enrolling people with narcolepsy with cataplexy (only) for a study of the efficacy of AXS-12 (reboxetine) for treatment of cataplexy and excessive daytime sleepiness. AXS-12 is an oral norepinephrine reuptake inhibitor (NRI).


A Study to Evaluate the Safety and Efficacy of TS-091 in Patients With Narcolepsy

RECRUITMENT COMPLETE Fall 2019, in Japan and S. Korea: CLICK HERE for the ClinicalTrials.gov listing. Taisho Pharmaceutical's TS-091 is a histamine H3 receptor inverse agonist (similar to pitolisant). As of October 2019, the study of TS-091 appears to have been discontinued for both hypersomnia and narcolepsy. Read more HERE.


The PATH Study: Psychosocial Adjunctive Treatment for Hypersomnia

RECRUITING COMPLETE as of August 2019: CLICK HERE for more information. The purpose of this study was to develop and test a new psychological treatment designed to improve psychosocial functioning in people with hypersomnia.

Results: 


Investigation of Clinical Feature and Brain Function in Narcoleptic Patients

RECRUITMENT STATUS unknown; study completion date was scheduled for December 2019: CLICK HERE.


Exploration of the Reward System by Functional MRI in Narco-Cataplexy Patients With and Without REM Sleep Behavior Disorder

RECRUITMENT STATUS unknown; study completion date was scheduled for June 2019: CLICK HERE.


XW Labs’ Phase 1 Study in Australia for Treatment of Narcolepsy With XW10172

Study completed May 2019. See XW Labs Initiates First-in-Human Phase I Study for Novel Narcolepsy Treatment. More information at the Australian New Zealand Clinical Trials Registry.

May 2021: XWPharma Announces Abstract for XW10172 Accepted for Presentation at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting.

"XW10172 is a conjugate of the GABAB receptor agonist, oxybate, that is in development as a modified release formulation intended to provide the desired tolerability and efficacy based on once-nightly dosing. The drug and formulation are designed to deliver oxybate without the sodium content of other products that is associated with increased cardiovascular health risk and monitoring requirements. The company plans to develop XW10172 for treatment of sleep disorders associated with neurodegenerative diseases, starting with excessive daytime sleepiness in patients with Parkinson’s disease and cataplexy and excessive daytime sleepiness in patients with narcolepsy."


Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients

RECRUITMENT COMPLETE as of Fall 2018: see clinicaltrials.gov. Theranexus' THN102 is a combination of modafinil and flecanide combo. Flecainide is "an antiarrhythmic agent used in this instance at very low dosages and for its modulating effects on the glial connexins.”

Results:


Umecrine Cognition’s Phase IIa Study of GR3027 in Patients With IH

RECRUITING COMPLETE as of Fall 2018. GR3027 was originally developed with the intention to reverse the hypersomnolence and impairments in cognition that occur in the clinical setting of liver failure – aka, hepatic encephalopathy. In October of 2017, Umecrine Cognition expanded their study of GR3027 to IH (see Umecrine Cognition Expands Study of New Medicine GR3027 to IH). 

In January, 2019, Umecrine Cognition announced their overall results from their Phase 2a Study. The primary study objectives were met in regard to safety and pharmacokinetics and also showed preliminary evidence of clinical efficacy. CLICK HERE to find out more about these results.

As of November, 2020, although GR3027 continues to be tested for liver failure, there has been no further development for IH. Read more HERE.


Survey Study on Autonomic Impairment in Adults With Idiopathic Hypersomnia (IH)

RECRUITING COMPLETE as of September 2018. In 2018, HF promoted this Stanford University-based survey study of autonomic impairment in adults with IH. Autonomic dysfunction includes symptoms like dizziness, bowel or bladder trouble, and temperature and heart rate dysregulation.

Results:

  • May 2019 Autonomic Symptom Burden in Idiopathic Hypersomnia: abstract published as part of the annual meeting of the AAN (American Academy of Neurology). The researchers found that people with IH reported extremely high levels of autonomic dysfunction, on par with other conditions of severe autonomic failure, like MSA (multiple system atrophy) and diabetes. “Symptoms of ANS impairment, sleepiness, and fatigue are more severe in individuals with IH compared to controls. Moreover, ANS symptom burden correlates moderately with higher levels of sleepiness and fatigue.” The researchers also hope to complete follow-up studies and provide a more detailed exploration of the potential mechanisms involved. "Future analysis will focus on COMPASS [composite autonomic symptom score-31] subscores and objective autonomic testing to help identify symptomatic domains, with the goal of more focused therapeutic targets for patients with IH."
  • May 2020 Frequency and severity of autonomic symptoms in idiopathic hypersomnia: publication in the Journal of Clinical Sleep Medicine.

To read our original SomnusNooze article about this study, CLICK HERE.


Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson’s Disease

RECRUITMENT STATUS UNKNOWN, in S. Korea: CLICK HERE. Study was scheduled for completion May 2017. Medicine available for off-label treatment in the U.S.


BUNIHPPS—An Online Research Survey for Patients With Narcolepsy & IH

In 2015, a research team at Boston University developed BUNIHPPS—a survey research study for patients with narcolepsy and idiopathic hypersomnia. Also called the Boston University Narcolepsy and Idiopathic Hypersomnia Patient Perspectives Study, BUNIHPPS was an anonymous online survey forging into new frontiers by asking patients about their experiences with symptoms, the diagnostic process, and their attitudes and behaviors. Dr. William DeBassio, a pediatric neurologist, and Sara Kowalczyk, a doctoral student at Boston University, were the study investigators. For more information, CLICK HERE.

Results:


The TONES Study (Jazz Pharmaceuticals’ JZP-110/Solriamfetol)

In 2015, doctors began conducting the TONES medical research study of an investigational product (JZP-110) designed to treat sleepiness and to help adults stay awake. The researchers wanted to evaluate the product’s effectiveness against excessive sleepiness when taken once a day for 12 weeks. Participants had to have been diagnosed with narcolepsy and sleeping at least 6 hours a night. For further info, CLICK HERE.

Results of related research into JZP-110:


Health and Well-Being in Those With and Without a Disorder of Daytime Sleepiness—A Research Survey From Australia

In 2015, Victoria University in Melbourne, Australia, commenced a study about the general health and well-being of people within three groups. The first group was those people with both narcolepsy and cataplexy. (Cataplexy is a sudden loss of muscle tone, often triggered by emotional arousal.) The second group was people with either narcolepsy-without-cataplexy or idiopathic hypersomnia. The third group had no disorders of excessive daytime sleepiness. This project was part of a PhD program by Samantha Gauci (under the supervision of Prof. Dorothy Bruck and Dr. Warwick Hosking). One question in the study was whether the presence of cataplexy in narcolepsy was associated with a different level of general health and well-being (and some symptoms such as pain and migraines).

Results:

Disclaimer

The contents of this website, including text, graphics and other material, are for informational purposes only. This website is not intended to be a substitute for professional legal or medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Always consult your own attorney or other legal advisor with any legal questions you may have. The Hypersomnia Foundation does not recommend or endorse any specific tests, physicians, lawyers, legal advisors, products, procedures, opinions or other information referenced on this website. Reliance on any information on this website is solely at your own risk.

The Hypersomnia Foundation makes no representations or warranties about the satisfaction of any government regulations requiring disclosure of information on prescription drug products. In no event shall The Hypersomnia Foundation be liable for any damages (including without limitation incidental and consequential damages) or costs (including without limitation attorney’s fees) based on any claim arising from the use of this website and/or its content.